X chromosomal abnormalities in basal-like human breast cancer.

By A. Richardson, Z. Wang, A. Nicolo, Xin Lu, Myles A. Brown, A. Miron, Xiaodong Liao, J. D. Iglehart, D. Livingston, Shridar Ganesan. Cancer Cell, 2006

871 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0f37000b63f0e4de4f6d31dd288a60e8d4f62c06

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

Citations in the corpus

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures (2008, methodology): “Almost all BRCA1-mutated tumors are confined to ER- tumors (Figure 1b), confirming the hypothesis that ER- ('basal-like') tumors are phenocopies of BRCA1-mutated tumors [14].”
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization (2011, background): “Similarly, gene expression profiling of an independent set of human breast cancer samples (Richardson et al., 2006) revealed that 25% of breast cancers exhibited at least a 6-fold reduction in the mRNA of SIRT3 compared to normal breast epithelium (Figure S5I).”
BRCA1 dysfunction in sporadic basal-like breast cancer (2007, background): “Another reported that BRCA1 expression and nuclear focus formation was retained in basal-like cancers (Richardson et al., 2006).”
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer (2011, methodology): “…persons) and breast cancer cell lines (92 lines), and analyzed the expression of vimentin, AXL, PLAU, RAB25, ITGB4, KRT6B (keratin 6B) and KLK5 (Richardson et al., 2006; Loi et al., 2007; Turashvili et al., 2007; Lu et al., 2008b; Marty et al., 2008; Bos et al., 2009; Burga et al., 2009; Chen…”
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers (2010, neutral): “We examined 53BP1 mRNA expression in these different subclasses in a combined dataset that includes the published datasets of two previous report”
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016, background): “Sporadic (BRCA1 and BRCA2 germline wild type) TNBCs share many characteristics with BRCA1 mutation-associated cancers, including a basal-like gene expression profile, frequent p53 mutations, and a high burden of genomic aberrations such as loss of heterozygosity (1-7).”